Pharmaceutical and life sciences
Product and territory margin, after every claim and return
Pharmaceutical margin is decided after the sale, by claims, expiry returns and scheme settlements. We account for those against the product and territory that generated them.
Margin after the trade takes its share.
Claims · expiry returns · schemes, by batch
At a glance
Expiry returns are recognised when claimed rather than provided for when the risk arises.
Margin after the chain
Product and territory contribution, net of all trade costs.
8 trades
Each trade runs on different numbers, so each has its own page
Open the one that matches your business. Each sets out how the money moves, where it usually breaks down and what we would do first.
The economics
Why the numbers are harder here
A pharmaceutical business sells through a distribution chain that takes its margin in arrears: stockist and distributor claims, expiry returns, breakage and scheme settlements all arrive after the invoice, often months after, and frequently against stock sold in an earlier period.
Meanwhile inventory is batch-controlled with a finite shelf life, so the cost of holding it is not only capital but obsolescence on a known clock. A product line can look profitable on primary sales and lose money once returns and write-offs are attributed to it.
The problem
Where visibility breaks down
- Expiry returns are recognised when claimed rather than provided for when the risk arises.
- Distributor and stockist claims are settled without being tested against the scheme that permitted them.
- Batch-level stock in the trade is unknown, so return exposure cannot be estimated.
- Field force expenses are approved without being attributable to a territory or product.
- Product profitability is measured on primary sales, before secondary-level cost.
Where we concentrate
How we focus the engagement
Margin after the chain
- Product and territory contribution, net of claims, returns and schemes.
- Expiry return provision computed on a stated basis rather than recognised on claim.
- Claims tested against the scheme terms before settlement.
- Field force cost attributed to territory and product.
- Primary and secondary sales reconciled, so the trade position is known.
Inventory and control
- Batch and expiry tracking through to the books, not only in operations.
- Ageing by batch, with the write-off exposure quantified in advance.
- Physical-to-book reconciliation on a fixed cycle, including at depots.
- Cold chain and breakage losses recorded as cost with a cause.
- Documentation retained to the standard a regulatory inspection expects.
Reporting
Reports worth receiving
- Product and territory contribution, net of all trade costs.
- Expiry exposure by batch and month.
- Claims raised, tested and settled.
- Primary against secondary sales.
- Inventory ageing and write-off provision.
Common questions
Questions we hear in this sector
Do you handle regulatory or quality compliance?
No. Our work is the finance function — costing, inventory accounting, claims, provisioning, controls and reporting. Drug regulatory, licensing and quality matters sit with the appropriate professionals and authorities.
How should expiry returns be provided for?
On a basis derived from your own history — return rates by product and shelf-life band — applied when the stock enters the trade rather than when the claim arrives. Recognising it on claim means the cost lands in a period unrelated to the sale that caused it.
Can you reconcile depot and distributor stock?
Yes. Knowing the batch-level position in the trade is what makes return exposure estimable rather than a surprise, and it is usually the first thing missing.
5th Quadrant performs finance, costing, inventory accounting and control work. Statutory audit, prescribed certification and any regulatory or quality attestation are performed by an independently engaged licensed professional or accredited body, coordinated through 5th Quadrant. Full detail is on our Professional Scope page.